Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(10):1542–1549. doi: 10.1038/sj.bjc.6690558

Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-D-arabinofuranosylcytosine in Daudi lymphoma cells

S K M Koller-Lucae 1, H Schott 2, R A Schwendener 1
PMCID: PMC2363091  PMID: 10408395

Abstract

Low density lipoprotein (LDL) receptor-mediated uptake and cytotoxic effects of N4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) were studied in Daudi lymphoma cells. NOAC was either incorporated into LDL or liposomes to compare specific and unspecific uptake mechanisms. Binding of LDL to Daudi cells was not altered after NOAC incorporation (KD 60 nM). Binding of liposomal NOAC was not saturable with increasing concentrations. Specific binding of NOAC-LDL to Daudi cells was five times higher than to human lymphocytes. LDL receptor binding could be blocked and up- or down-regulated. Co-incubation with colchicine reduced NOAC-LDL uptake by 36%. These results suggested that NOAC-LDL is taken up via the LDL receptor pathway. In an in vitro cytotoxicity test, the IC50 of NOAC-LDL was about 160 μM, whereas with liposomal NOAC the IC50 was 40 μM. Blocking the LDL receptors with empty LDL protected 50% of the cells from NOAC cytotoxicity. The cellular distribution of NOAC-LDL or NOAC-liposomes differed only in the membrane and nuclei fraction with 13% and 6% respectively. Although it is more convenient to prepare NOAC-liposomes as compared to the loading of LDL particles with the drug, the receptor-mediated uptake of NOAC-LDL provides an interesting rationale for the specific delivery of the drug to tumours that express elevated numbers of LDL receptors. © 1999 Cancer Research Campaign

Keywords: ara-C, lipophilic derivative, low density lipoproteins, liposomes, Daudi cells, lymphocytes

Full Text

The Full Text of this article is available as a PDF (140.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe I., Saito S., Hori K., Suzuki M., Sato H. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res. 1982 Jul;42(7):2846–2851. [PubMed] [Google Scholar]
  2. Allison B. A., Pritchard P. H., Levy J. G. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer. 1994 May;69(5):833–839. doi: 10.1038/bjc.1994.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Firestone R. A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem. 1994 Mar-Apr;5(2):105–113. doi: 10.1021/bc00026a002. [DOI] [PubMed] [Google Scholar]
  4. Goldstein J. L., Basu S. K., Brown M. S. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 1983;98:241–260. doi: 10.1016/0076-6879(83)98152-1. [DOI] [PubMed] [Google Scholar]
  5. Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930. doi: 10.1146/annurev.bi.46.070177.004341. [DOI] [PubMed] [Google Scholar]
  6. Horber D. H., Schott H., Schwendener R. A. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol. 1995;36(6):483–492. doi: 10.1007/BF00685798. [DOI] [PubMed] [Google Scholar]
  7. Horber D. H., Schott H., Schwendener R. A. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer. 1995 May;71(5):957–962. doi: 10.1038/bjc.1995.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Horber D. H., von Ballmoos P., Schott H., Schwendener R. A. Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine. Br J Cancer. 1995 Nov;72(5):1067–1073. doi: 10.1038/bjc.1995.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jasanada F., Urizzi P., Souchard J. P., Le Gaillard F., Favre G., Nepveu F. Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): evaluation as a potential radiopharmaceutical for tumor localization. Bioconjug Chem. 1996 Jan-Feb;7(1):72–81. doi: 10.1021/bc950073l. [DOI] [PubMed] [Google Scholar]
  10. Koller-Lucae S. K., Schott H., Schwendener R. A. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. J Pharmacol Exp Ther. 1997 Sep;282(3):1572–1580. [PubMed] [Google Scholar]
  11. Koller-Lucae S. K., Suter M. J., Rentsch K. M., Schott H., Schwendener R. A. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice. Drug Metab Dispos. 1999 Mar;27(3):342–350. [PubMed] [Google Scholar]
  12. MacCoss M., Edwards J. J., Lagocki P., Rahman Y. E. Phospholipid-nucleoside conjugates. 5. The interaction of selected 1-beta-D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-diacylglycerols with serum lipoproteins. Biochem Biophys Res Commun. 1983 Oct 31;116(2):368–374. doi: 10.1016/0006-291x(83)90531-4. [DOI] [PubMed] [Google Scholar]
  13. Morrison I. E., Anderson C. M., Georgiou G. N., Stevenson G. V., Cherry R. J. Analysis of receptor clustering on cell surfaces by imaging fluorescent particles. Biophys J. 1994 Sep;67(3):1280–1290. doi: 10.1016/S0006-3495(94)80600-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rensen P. C., Schiffelers R. M., Versluis A. J., Bijsterbosch M. K., Van Kuijk-Meuwissen M. E., Van Berkel T. J. Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol Pharmacol. 1997 Sep;52(3):445–455. doi: 10.1124/mol.52.3.445. [DOI] [PubMed] [Google Scholar]
  15. Rinninger F., Brundert M., Jäckle S., Kaiser T., Greten H. Selective uptake of low-density lipoprotein-associated cholesteryl esters by human fibroblasts, human HepG2 hepatoma cells and J774 macrophages in culture. Biochim Biophys Acta. 1995 Mar 16;1255(2):141–153. doi: 10.1016/0005-2760(94)00228-q. [DOI] [PubMed] [Google Scholar]
  16. Rubas W., Supersaxo A., Weder H. G., Hartmann H. R., Hengartner H., Schott H., Schwendener R. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer. 1986 Jan 15;37(1):149–154. doi: 10.1002/ijc.2910370123. [DOI] [PubMed] [Google Scholar]
  17. Stephan Z. F., Yurachek E. C. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J Lipid Res. 1993 Feb;34(2):325–330. [PubMed] [Google Scholar]
  18. Swanson J., Bushnell A., Silverstein S. C. Tubular lysosome morphology and distribution within macrophages depend on the integrity of cytoplasmic microtubules. Proc Natl Acad Sci U S A. 1987 Apr;84(7):1921–1925. doi: 10.1073/pnas.84.7.1921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Viallard V., Lacombe C., Trocheris V., Tabacik C., Aliau S. Metabolism of low-density lipoprotein in differentiated and undifferentiated HT29 colon cancer cells. Int J Cancer. 1990 Aug 15;46(2):320–325. doi: 10.1002/ijc.2910460230. [DOI] [PubMed] [Google Scholar]
  20. Vitols S., Söderberg-Reid K., Masquelier M., Sjöström B., Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer. 1990 Nov;62(5):724–729. doi: 10.1038/bjc.1990.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Vogler W. R., Olson A. C., Okamoto S., Shoji M., Raynor R. L., Kuo J. F., Berdel W. E., Eibl H., Hajdu J., Nomura H. Comparison of selective cytotoxicity of alkyl lysophospholipids. Lipids. 1991 Dec;26(12):1418–1423. doi: 10.1007/BF02536579. [DOI] [PubMed] [Google Scholar]
  22. Wasan K. M., Ramaswamy M., Cassidy S. M., Kazemi M., Strobel F. W., Thies R. L. Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob Agents Chemother. 1997 Sep;41(9):1871–1875. doi: 10.1128/aac.41.9.1871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yen C. F., Kalunta C. I., Chen F. S., Kaptein J. S., Lin C. K., Lad P. M. Flow cytometric evaluation of LDL receptors using DiI-LDL uptake and its application to B and T lymphocytic cell lines. J Immunol Methods. 1994 Dec 28;177(1-2):55–67. doi: 10.1016/0022-1759(94)90143-0. [DOI] [PubMed] [Google Scholar]
  24. Yen C. F., Kalunta C. I., Chen F. S., Kaptein J. S., Lin C. K., Lad P. M. Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells. Biochim Biophys Acta. 1995 Jun 27;1257(1):47–57. doi: 10.1016/0005-2760(95)00051-d. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES